Skip to main content
Fig. 5 | Journal of Translational Medicine

Fig. 5

From: Efficacy and safety of immunosuppressants and monoclonal antibodies in adults with myasthenia gravis: a systematic review and network meta-analysis

Fig. 5

Funnel plots for efficacy and safety outcomes: (A) MG-ADL, (B) QMG, (C) MGC, (D) MG-QoL 15r, (E) AEs, and (F) SAEs. MG-ADL, Myasthenia Gravis Activities of Daily Living; QMG, Quantitative Myasthenia Gravis; MGC, Myasthenia Gravis Composite; MG-QoL 15r, 15-item revised version of the Myasthenia Gravis Quality of Life; AEs, adverse events; SAEs, severe adverse events

Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us